ScholarIQanswers from OpenAlex & ORCID
Bruno Sangro
ResearcherPublications, citations & collaboration network
Bruno Sangro is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Bruno Sangro have?
ScholarIQindexed works
Bruno Sangro has 805 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Bruno Sangro have?
ScholarIQcitation count
Bruno Sangro has 50,472 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Bruno Sangro?
ScholarIQh-index
Bruno Sangro has an h-index of 97 in OpenAlex.
What is the i10-index of Bruno Sangro?
ScholarIQi10-index
Bruno Sangro has an i10-index of 327 in OpenAlex.
What is the ORCID of Bruno Sangro?
ScholarIQorcid
The ORCID for Bruno Sangro is on the source record.
What is the OpenAlex record for Bruno Sangro?
ScholarIQopenalex
The OpenAlex for Bruno Sangro is on the source record.
What are the most-cited papers on Bruno Sangro?
ScholarIQmost cited works
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Bruno Sangro, Josepmaria Argemi, Maxime Ronot, Valérie Paradis, Tim Meyer, Vincenzo Mazzaferro, Peter Jepsen, Rita Golfieri, Peter R. Galle, Laura A. Dawson, María Reig
Survival after Yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation
Bruno Sangro, L Carpanese, Roberto Cianni, Rita Golfieri, Daniele Gasparini, Samer Ezziddin, Philipp M. Paprottka, Francesco Fiore, Mark Van Buskirk, José Ignacio Bilbao, Giuseppe Maria Ettorre, Rita Salvatori, Emanuela Giampalma, Onelio Geatti, Kai Wilhelm, Ralf Hoffmann, Francesco Izzo, Mercedes Iñarrairaegui, C.L. Maini, Carlo Urigo, Alberta Cappelli, Alessandro Vit, Hojjat Ahmadzadehfar, Tobias F. Jakobs, Secondo Lastoria
Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma
Jens Ricke, Heinz‐Josef Klümpen, Holger Amthauer, Irene Bargellini, Peter Bartenstein, Enrico N. De Toni, Antonio Gasbarrini, Maciej Pech, Markus Peck‐Radosavljevic, Peter Popovič, Olivier Rosmorduc, Eckart Schott, Max Seidensticker, Chris Verslype, Bruno Sangro, Peter Malfertheiner
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
Bruno Sangro, Bruno Sangro, Masatoshi Kudo, Joseph P. Erinjeri, Shukui Qin, Zhenggang Ren, Stephen L. Chan, Yasuaki Arai, Jeong Heo, Anh Mai, Jose Escobar, Yamil Alonso Lopez Chuken, Jung-Hwan Yoon, Won Young Tak, Valeriy V Breder, Tanita Suttichaimongkol, Mohamed Bouattour, Shi-Ming Lin, Jean-Marie Peron, Quang T Nguyen, Lünan Yan, Chang-Fang Chiu, Florinda A Santos, Anil Veluvolu, Satheesh Chiradoni Thungappa, Marco Matos, Magdalena Żotkiewicz, Stephanie I. Udoye, John F. Kurland, G. Cohen, Riccardo Lencioni, Kathia Cristina Abdalla, Manon Allaire, Gustavo R. Alves, Luís Carlos Moreira Antunes, Eric Assénat, Sérgio Jobim Azevedo, Rafael Barreto, Muhammad Shaalan Beg, Glaucio Bertollo, Jean‐Frédéric Blanc, Mohamed Bouattour, Rakesh Reddy Boya, Valery Breder, Jean–Pierre Bronowicki, Manoch Buranachokphaisan, Adam M. Burgoyne, Stephen L. Chan, Ting‐Tsung Chang, Yee Chao, Eric Chen, Xiaoming Chen, Chang-Fang Chiu, Minsig Choi, SUNGHEE CHOI, Natalie G. Coburn, Luis Contreras, Farshid Dayyani, Thomas Decaens, Arunee Dechaphunkul, Maria del Consuelo Diaz, Anouk Dev, Jamille Dutra, Melissa Eastgate, Jose Escobar, Bassam Estfan, Vittorio Ferrari, Anne-Claire Frin, Sandip Ganguly, Ranga Raman Ganta, Shanzhi Gu, Yabing Guo, Atsushi Hagihara, Jeong Heo, Chih‐Hung Hsu, Jimmy Hwang, Yoshitaka Inaba, Shikha Jain, D. Jonker, Shruti Kate, Shruti Kate, Naoya Kato, Tomokazu Kawaoka, Kwong‐Ming Kee, Seung Up Kim, Kiyohide Kioka, Hironori Koga, Masatoshi Kudo, Hidekatsu Kuroda, Phuong Uyen Le, Han-chu Lee, Joon Hyeok Lee, Teng-Yu Lee, Dongliang Li, Hailiang Li, Wei Li, Xiao Li, Cheng-Yao Lin, Shi-Ming Lin, Yamil Lopez